Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK
Crossref DOI link: https://doi.org/10.1007/s12325-019-0894-2
Published Online: 2019-02-06
Published Print: 2019-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McCarthy, Grant
Fenu, Elisabetta
Bennett, Natalie
Almond, Chrissy
Text and Data Mining valid from 2019-02-06
Article History
Received: 20 December 2018
First Online: 6 February 2019